Alps Advisors Inc Revance Therapeutics, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 04, 2019	SELL	$18.06 - $24.96 $1.18 Million - $1.63 Million	-65,366 Closed	0 $0
Q3 2018 Oct 25, 2018	BUY	$23.55 - $30.1 $281,469 - $359,755	11,952 Added 22.38%	65,366 $1.62 Million
Q2 2018 Aug 02, 2018	BUY	$27.45 - $33.35 $525,255 - $638,152	19,135 Added 55.82%	53,414 $1.47 Million
Q2 2018 Jul 25, 2018	SELL	$27.45 - $33.35 $376,119 - $456,961	-13,702 Reduced 28.56%	34,279 $1.23 Million
Q1 2018 May 01, 2018	BUY	$29.15 - $37.4 $399,413 - $512,454	13,702 Added 39.97%	47,981 $1.48 Million
Q4 2017 Feb 05, 2018	BUY	$24.55 - $36.3 $96,432 - $142,586	3,928 Added 12.94%	34,279 $1.23 Million
Q3 2017 Nov 03, 2017	BUY	$22.55 - $28.1 $684,415 - $852,863	30,351	30,351 $836,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.